Transparency Notifications from Shareholders

*PRESS RELEASE*
*REGULATED INFORMATION*

8 April 2024, 06:30 pm CEST

*Ghent, Belgium – 8 April 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) *(the "*Company*" or "*Sequana* *Medical*"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it received transparency notifications from the shareholders listed below, notifying the number of voting rights attached to shares mentioned next to their respective names in the table below.

The transparency notifications were filed following a private placement of new shares that was announced and priced on 20 March 2024, with pricing announced on 21 March 2024, by means of a private placement through an accelerated bookbuilding procedure of new shares.
*Reason for notification* *Aggregate number of shares and voting rights held* *% of total outstanding shares*^*(1)*
Optiverder B.V.^(^2^) Passive crossing of a threshold / Downward crossing of the lowest threshold 922,535 2.57%
Société Fédérale de Participations et d'Investissement SA - Federale Participatie- en Investeringsmaatschappij NV / Belfius Insurance SA ^(3^) Passive crossing of a threshold 1,910,199 5.32%
GRAC société simple^ (^4^) Acquisition of voting securities or voting rights 1,858,097 5.17%

_____________
Notes:

(1) The total number of outstanding shares of the Company mentioned in the relevant transparency notifications amounts to 35,909,420, each share giving right to one (1) vote (being 35,909,420 voting rights in total).
(2) A parent undertaking or a controlling person of Optiverder B.V. ("*Optiverder*"), informed the Company, by means of a notification dated 3 April 2024, that on 25 March 2024 Optiverder’s aggregate number of voting rights passively crossed below the lowest threshold of 3% of the outstanding voting rights of the Company. The notification furthermore specifies that the participation is held by Mr. C.A.C.M. Oomen through its 100% owned personal holding Optiverder.
(3) A parent undertaking or a controlling person of Société Fédérale de Participations et d'Investissement SA / Federale Participatie- en Investeringsmaatschappij NV ("*SFPI-FPIM*"), Belfius Banque SA ("*Belfius Bank*") and Belfius Insurance SA ("*Belfius Insurance*"), informed the Company, by means of a joint notification dated 2 April 2024, that on 25 March 2024 the aggregate shareholding of Belfius Insurance (holding 24,393 shares and voting rights; which corresponds to 0.07% of the outstanding voting rights of the Company) had passively crossed below the lowest threshold of 3% of the outstanding voting rights of the Company. The joint notification specifies furthermore that SFPI-FPIM (holding 1,885,806 shares and voting rights; which corresponds to 5.25% of the outstanding voting rights of the Company) is the parent company of Belfius Bank (ex Dexia Banque SA), which in its turn is the parent company of Belfius Insurance. The notification also states that SFPI-FPIM acts in its own name, but on behalf of the Belgian State and that it is owned for 100% by the Belgian State. It follows from the notification that Belfius Bank does not own any voting securities or voting rights in the Company.
(4) GRAC société simple ("*GRAC*"), acting as a person that notifies alone, informed the Company, by means of a notification dated 28 March 2024, that on 25 March 2024 the aggregate number of voting rights of GRAC actively crossed the threshold of 5% of the outstanding voting rights of the Company. The notification furthermore specifies that GRAC is not controlled by another entity or holding.

This announcement is made in accordance with Article 14 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions.

To access copies of the aforementioned transparency notifications, reference is made to Sequana Medical's website (https://www.sequanamedical.com/investors/shareholder-information/).

Pursuant to the Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority (FSMA) is required by all natural and legal persons in each case where the percentage of voting rights attached to the securities held by such persons in the Company reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.

*For more information, please contact:*

*Sequana Medical*

Lies Vanneste
Director Investor Relations
E: IR@sequanamedical.com
T: +32 (0)498 05 35 79

*About Sequana Medical*

Sequana Medical NV is a pioneer in treating fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and cancer. This causes major medical issues including increased mortality, repeated hospitalizations, severe pain, difficulty breathing and restricted mobility. Although diuretics are standard of care, they become ineffective, untolerable or exacerbate the problem in many patients. There are limited effective treatment options, resulting in poor clinical outcomes, high costs and a major impact on their quality of life. Sequana Medical is seeking to provide innovative treatment options for this large and growing "diuretic-resistant" patient population. *alfa*pump® and DSR® are Sequana Medical's proprietary platforms that work with the body to treat diuretic-resistant fluid overload, delivering major clinical and quality of life benefits for patients and reducing costs for healthcare systems.

The Company's Premarket Approval (PMA) application for the *alfa*pump was submitted to the US FDA in December 2023 and accepted for substantive review in January 2024, having reported positive primary and secondary endpoint data from the North American pivotal POSEIDON study in recurrent or refractory ascites due to liver cirrhosis.

Results of the Company's RED DESERT and SAHARA proof-of-concept studies in heart failure support DSR's mechanism of action as breaking the vicious cycle of cardiorenal syndrome. All three patients from the non-randomized cohort of MOJAVE, a US randomized controlled multi-center Phase 1/2a clinical study, have been successfully treated with DSR, resulting in a dramatic improvement in diuretic response and virtual elimination of loop diuretic requirements. The independent Data Safety Monitoring Board approved the start of the randomized MOJAVE cohort of up to a further 30 patients, which is planned after *alfa*pump US PMA approval.

Sequana Medical is listed on the regulated market of Euronext Brussels (Ticker: SEQUA.BR) and headquartered in Ghent, Belgium. For further information, please visit www.sequanamedical.com.

*Important Regulatory Disclaimers*

The *alfa*pump® system is currently not approved in the United States or Canada. In the United States and Canada, the *alfa*pump system is currently under clinical investigation (POSEIDON Trial) and is being studied in adult patients with refractory or recurrent ascites due to liver cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between DSR therapy and ongoing investigations with the *alfa*pump system in Europe, the United States or Canada.

Note: *alfa*pump® and DSR® are registered trademarks.

*Forward-looking statements*

This press release may contain predictions, estimates or other information that might be considered forward-looking statements.
Such forward-looking statements are not guarantees of future performance. These forward-looking statements represent the current judgment of Sequana Medical on what the future holds, and are subject to risks and uncertainties that could cause actual results to differ materially. Sequana Medical expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.

*Attachments*

· Press release_Transparency notification_NL_8 April 2024_vF
· Press release_Transparency notification_ENG_8 April 2024_vF